期刊文献+

逐瘀还五解毒颗粒治疗冠心病心绞痛临床研究 被引量:3

Clinical Research of Zhuyu Huanwu Jiedu Granule in Treating Coronary Angina Pectoris
下载PDF
导出
摘要 目的:探讨逐瘀还五解毒颗粒对冠心病心绞痛的症状及心电图变化的影响,评估逐瘀还五解毒颗粒治疗冠心病心绞痛的临床疗效。方法:将94例冠心病心绞痛患者随机分为两组,对照组给予基础西药治疗,治疗组在对照组治疗基础上加用逐瘀还五解毒颗粒(方药组成:桃仁12 g,红花9 g,当归9 g,生地黄9 g,川芎4.5 g,赤芍6 g,牛膝9 g,桔梗4.5 g,柴胡3 g,枳壳6 g,甘草6 g,黄芪18 g,地龙9 g,金银花12 g,蒲公英12 g)治疗,2周为1个疗程。结果:治疗组患者的症状及心电图的改善明显优于对照组。结论:逐瘀还五解毒颗粒治疗冠心病心绞痛疗效满意。 Objective:To explore the influence of Zhuyu Huanwu Jiedu granule on coronary angina pectoris on clinical symptoms and electrocardiogram changes and evaluate the clinical effects of zhuyu huanwu jiedu granule in treating coronary angina pectoris.Methods:94 cases of coronary angina pectoris were randomly divided into two groups.The control group was treated by basic western medicine.The treatment group was orally given Zhuyu Huanwu Jiedu granule(composition:peach kernel 12 g,safflower 9 g,Angelica 9 g,dried rehmannia root 9 g,hemlock parsley 4.5 g,red peony root 6 g,Achyranthes bidentata 9 g,Platycodon grandiflorum 4.5 g,Chinese thorowax 3 g,fructus 6 g,licorice root 6 g,Astragalus membranaceus 18 g,Earthworm 9 g,honeysuckle 12 g,dandelion12 g) based on the control group.2 weeks were one treatment course for both groups.Results:Patients′ clinical symptoms and the improvement of electrocardiogram in the treatment group were obviously superior to the control group.Conclusion:Zhuyu Huanwu Jiedu granule has a satisfactory therapeutic effect in treating coronary angina pectoris.
出处 《中医学报》 CAS 2012年第10期1327-1328,共2页 Acta Chinese Medicine
关键词 冠心病心绞痛 逐瘀还五解毒颗粒 硝酸酯类 β受体阻滞剂 钙拮抗剂 抗血小板及调血脂药物 coronary angina pectoris zhuyu huanwu jiedu granule nitrates beta-blocker calcium antagonists antiplatelet drug and liporegulators
  • 相关文献

参考文献7

二级参考文献10

  • 1Luc G, Bard J M, Arveiler D, et al. Lipoprotein (a) as a predictor of coronary heart disease: The PRIME Study. Atherosclerosis, 2001,163(2):377-384.
  • 2Seman L G, Deluca C, Jenner J L,et al. Lipoprotein (a)-cholesterol and coronary heart disease in the Framingham Heart Study. Clin Chem, 1999,45(7):1039-1046.
  • 3Lundstam U, Herlitz J, Karlsson T, et al. Serum lipids, lipoprtein (a) level, and apolipoprotein(a) isoforms as prognostic markers in patients with coronary heart disease. J Intern Med, 2002,251(2):111-118.
  • 4Marcovina S M, Hegele R A, Koschinsky M L. Lipoprotein (a) and coronary heart disease risk. Curr Cardiol Rep,1999,1(2):105-111.
  • 5Angles C E. Structural basis for the pathophysiology of lipoprotein(a) in the athero-thrombotic process. Braz J Med Biol Res,1997,30(11):1271-1280.
  • 6Maeda S, Abe A, Seishima M, et al. Transient change of serum lipoprotein (a) as an acute phase protein. Atherosclerosis, 1989,78(1):145-150.
  • 7Greory Y H, Gordon D L. Fibrin D-dimer: A useful marker of thrombogenesis? Clini Sci,1995(89):205-214.
  • 8王达理,曾爱萍,南柏松.心肌细胞培养方法和活细胞噻唑兰法测定[J].空军医高专学报,1999,21(4):191-193. 被引量:7
  • 9陈文梅,金鸣,李金荣,吴伟.红花黄色素对羟自由基损伤抗凝血酶Ⅲ的保护作用[J].心肺血管病杂志,1998,17(3):215-217. 被引量:41
  • 10金鸣,李金荣,蔡亚欣,刘军,秦兰萍.红花水溶性成分抗氧化作用的研究[J].心肺血管病杂志,1998,17(4):277-279. 被引量:66

共引文献501

同被引文献30

引证文献3

二级引证文献59

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部